Genmab (CPH:GMAB) Third Quarter 2024 Results
Key Financial Results
- Revenue: kr.5.54b (up 17% from 3Q 2023).
- Net income: kr.1.27b (down 41% from 3Q 2023).
- Profit margin: 23% (down from 45% in 3Q 2023). The decrease in margin was driven by higher expenses.
- EPS: kr.19.94 (down from kr.32.60 in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Genmab Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 1.9%. Earnings per share (EPS) also missed analyst estimates by 8.4%.
Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe.
Performance of the market in Denmark.
The company's shares are up 3.6% from a week ago.
Balance Sheet Analysis
While earnings are important, another area to consider is the balance sheet. We've done some analysis and you can see our take on Genmab's balance sheet.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About CPSE:GMAB
Genmab
Develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.
Flawless balance sheet and undervalued.
